Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Clasificación en acciones #21012
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Precio por acción
$7.12
Última sincronización: 2023-03-08
Capitalización bursátil
$117.03M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
GB
Comercio F-star Therapeutics, Inc. (FSTX)

Categoría

Historial del precio de la acción de F-star Therapeutics, Inc. (FSTX)
Precio más alto de cierre: $6.19 el 2023-03-01

Precio más bajo de cierre: $7.22 el 2021-05-01
Historial del precio de la acción de F-star Therapeutics, Inc. desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2023 14.14%
2022 6.74%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH